Acute Myeloic Leukemia (AML)
- The allopathic definition:
Malignant degeneration and dysmaturity of the blood-forming stem cells. In this regard the word acute means that leukemia cells occur morphologically as blasts and a major portion of blasts are present in the bone marrow (25%-30%).
- How frequently does AML occur (incidence rate) in Germany (USA appr. x 3)?
The current incidence rate is 2.5 per 100,000 people. On average the patients are over 60 years old. Primarily patients who were subjected to multiple incidences of radiation exposure (tumor therapy, radiation therapy, etc.) are affected. But also patients are affected after a chemotherapy.
M0 – M7
- How is this type of cancer diagnosed by allopathic practitioners?
Fatigue, fever, subcutaneous bleeding (ecchymosis), paleness, bone pain, general neurological symptoms, joint pain. Bone marrow punction (blast count greater than 25%) blood tests, (LDH, leucocytes, Hb, thrombocytes, GOT, GPT, quick, PTT, PTZ, fibronogen, lysozyme, etc.), measurement of the liver and spleen size, testicular examination, ultrasound, CT. Bear in mind here that with hemograms can return values that are too high and too low. Many physicians also use the lactate dehydrogenase value (LDH) as a measurement value of the disease.
AML therapy means = chemotherapy. Here there are also statistics showing that patients who received chemotherapy survived the five-year threshold. Naturally what many patients do not know is that there are only a very few patients who have not been treated allopathically with this therapy, naturally again giving rise to the question; “do patients survive because of, or in spite of, the therapy?” Another point is also “forgotten” when allopathic therapy is recommended. After treatment with such an intensive chemotherapy that is used for AML, which as we know, is carcinogenic itself, there is no possibility of going back to a holistic therapy, because the damages caused by this therapy combination cannot be restored by any holistic therapy. In practical terms this means that the patient must decide for one direction or the other. The option of, “let’s test this first, and if it fails then we will pursue a different path”, is not possible in 99% of the cases.
In most therapeutic centers reference is made to the 4 steps of an AML treatment. These are:
- In the first phase, the induction phase, a lot of chemotherapy is used to bring the cancer illness into a remission. Here, naturally a CR (Complete Remission) is the objective. According to the allopathic view this is achieved when the medulla blast count is a maximum of 5%, the peripheral thrombocyte count is less than 100,000, and the peripheral granulocyte count exceeds 1,500. In this regard cytosinarabinoside (Ara-C), anthracyclines (such as daunorubicin or idarubicin), thioguanin and VP16 are primarily used. In many clinics the standard has become the TAD therapy (thioguanin, Ara-C, daunorubicin) followed by the HAM therapy (Ara-C, mitoxantrone).
The “M3 patients” are an exception in this case. M3 patients are patients with a promyelocyte leukemia. Patients with this clinical picture initially receive all-trans-retinoic-acid, because apparently studies have shown that the promyelocytic blasts “normalize” and then divide normally again. Unfortunately the side effects of this therapy are very dangerous (embolisms), so that usually this therapy is only used for a short time. Patients who do not respond to the above-named therapies, are referred to as Non-Responders by practitioners. I find this word very disrespectful; apparently no one has considered that it is not the patients, but rather the therapy that has failed. When referring to the patient as an NR, the underlying assumption is that the therapy was basically correct. What a fatal mistake for many patients.
- In the second phase, the so-called consolidation phase, the theory is to reduce the recurrence risk with significantly more chemotherapy. This understanding of therapy in my opinion, should be challenged because patients are given no time to recover from the induction therapy and it is believed/hoped that the patient is then healthy enough that he will survive further chemotherapies. Unfortunately many times I have had to experience that this is not the case.
It is also interesting to note that oncologists are not at all unified as to what a successful consolidation phase must look like. To take a heretical stance I could say: Since oncologists have no idea at all of which therapies can help their patients, they simply “to at it and therapise”. While many patients get allogenic or autologic stem cell transplants, others in turn are given high-dose chemotherapies with Ara-C or also another “normal” dose with Ara-C.
- In the third treatment phase, the so-called maintenance therapy, chemotherapies are usually administered in lower doses. I consider this approach to be questionable, since the chance of an immune/resistance relative to the previously higher, administered toxins is quite probable, and the question must really be asked in this case as to whether maintenance therapies are really anything more than unnecessary toxifications of the body.
- For relapses, usually so-called “second-line” therapies are offered. Collectively these can be referred to as: Yet more chemotherapies in all variations. In my opinion the helplessness of many oncologists is manifest here. In any field other than oncology, other strategies would be used if the old strategies have failed. But this is not the case in oncology. Here more is administered of what did not work previously. The only answer here is logic, logic, logic.
Bone marrow therapies (BMT)
A. Allogenic bone marrow transplant / stem cell transplant:
Here the patient receives stem cells from a donor. First high doses of chemotherapy are administered with or without supplemental radiation, in order to destroy all the bone marrow in the body. Then healthy bone marrow is taken from a different donor. The healthy bone marrow of the donor is then injected into the patient, and this then replaces the destroyed bone marrow of the patient. Unfortunately whether this really occurs is all to rarely investigated. I am not aware of precise test procedures that prove that new bone marrow is really just the bone marrow of the donor, and not partly new bone marrow produced by the patient himself. But as long as over 250,000 EURO are earned for each bone marrow patient, who is interested in answering this question?
B. Autologic bone marrow transplant / stem cell transplant:
In this therapy, bone marrow/stem cells are removed from the patient and re-administered to the patient after high-dose chemotherapy. This means that bone marrow is removed from the patient and treated with medication to kill all cancer cells. The bone marrow is frozen for storage. The patient then receives a high-dose chemotherapy with or without supplemental radiation, to destroy all the remaining bone marrow. The stored, frozen bone marrow is thawed and then injected back into the patient.
Naturally one should not forget that bone marrow transplant involves a high risk of the patient dying due to the therapy. Neither of these therapies is undisputed, even among allopathic practitioners.
Radiation and operations
Radiation or operations are not used for AML. If you are offered radiation, then immediately demand to know the reason why, three times.
Additional therapies like hormones, antibodies, etc.
There were studies and there are studies with antibodies e.g. CD3 (MAK). Here however it must clearly be stated that while these studies have not shown any significant advantages, they have shown many disadvantages.
Furthermore, in June 2000, one manufacturer of monoclonal antibodies, (Genentech), was compelled to send a warning letter to all physicians in the USA, warning of serious side effects, because 15 women died (within 24 hours of the infusion) through therapies with monoclonal antibodies.
Other medications like arsenic-trioxide, gene therapies etc. are currently being discussed and investigated. However again the question arises: Where are the convincing results?